Ling Ding
- Cancer Research top 2%
- MicroRNA in disease regulation 8
- Biomaterials top 2%
- Nanoparticle-Based Drug Delivery 12
- Immunology top 5%
- Immune cells in cancer 8
- Molecular Biology top 5%
- RNA Interference and Gene Delivery 16
- Advanced biosensing and bioanalysis techniques 11
- Oncology top 5%
- Cancer Immunotherapy and Biomarkers 10
-
- Dendrimers and Hyperbranched Polymers 17
-
- Nanoplatforms for cancer theranostics 15
- Journals
- Acta Pharmacologica Sinica (5 papers)Journal of Controlled Release (5 papers)Acta Pharmaceutica Sinica B (4 papers)
- Partner nations
- ChinaUnited StatesFrance
In The Last Decade
Ling Ding
129 papers receiving 4.2k citations
Hit Papers
Peers
Comparison fields: 5 of 125
- Cancer Research 800
- Biomaterials 507
- Immunology 729
- Molecular Biology 2.2k
- Oncology 662
Countries citing papers authored by Ling Ding
This map shows the geographic impact of Ling Ding's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ling Ding with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ling Ding more than expected).
Fields of papers citing papers by Ling Ding
This network shows the impact of papers produced by Ling Ding. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ling Ding. The network helps show where Ling Ding may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Ling Ding, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 2 | |
| 2 | 2024 | 9 | |
| 3 | 2024 | 4 | |
| 4 | 2024 | 4 | |
| 5 | 2022 | 8 | |
| 6 | 2022 | 27 | |
| 7 | 2022 | 2 | |
| 8 | 2022 | 12 | |
| 9 | 2022 | 1 | |
| 10 | 2022 | 25 | |
| 11 | 2021 | 36 | |
| 12 | 2021 | 4 | |
| 13 | 2021 | 27 | |
| 14 | 2021 | 48 | |
| 15 | 2020 | 8 | |
| 16 | Effect of dopamine neurotransmitter expression on sleep disorders in neurological inpatients | 2019 | 1 |
| 17 | 2018 | 98 | |
| 18 | 2017 | 53 | |
| 19 | 2015 | 57 | |
| 20 | 2013 | 18 |
About Ling Ding
Ling Ding is a scholar working on Polymers and Plastics, Cancer Research and Immunology, having authored 135 papers that have together received 4.2k indexed citations. Recurring topics across this work include Dendrimers and Hyperbranched Polymers (17 papers), RNA Interference and Gene Delivery (16 papers), Nanoplatforms for cancer theranostics (15 papers), Nanoparticle-Based Drug Delivery (12 papers), Advanced biosensing and bioanalysis techniques (11 papers), Cancer Immunotherapy and Biomarkers (10 papers), MicroRNA in disease regulation (8 papers) and Immune cells in cancer (8 papers). The work is most often cited by research in Cancer Research (800 citations), Biomaterials (507 citations) and Immunology (729 citations). Ling Ding has collaborated with scholars based in China, United States and France. Frequent co-authors include Qiaojun He, Bo Yang, Guikai Liang, Ling Peng, Jieqiong Zhang, Xi Chen, Yanjun Xu, David Oupický, Jianmin Si and Ying Du. Their work appears in journals such as Acta Pharmacologica Sinica, Journal of Controlled Release, Acta Pharmaceutica Sinica B, Proceedings of the National Academy of Sciences and European Journal of Pharmacology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.